<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi> (<z:chebi fb="0" ids="2038">5-azacytidine</z:chebi>, VIDAZA) is a disease-modifying agent that improves survival, reduces transfusion dependence, and reduces progression to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> in patients with higher risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi> injection is associated with characteristic adverse events (AEs) that must be managed in order for patients to stay on therapy and achieve optimal therapeutic outcomes </plain></SENT>
<SENT sid="2" pm="."><plain>These AEs include injection-site reactions, cytopenias, and gastrointestinal effects </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0002664'>Oncology</z:hpo> nurses are uniquely positioned to provide patient support and counselling, thereby helping patients and their families set clear expectations for <z:chebi fb="0" ids="2038">azacitidine</z:chebi> therapy </plain></SENT>
<SENT sid="4" pm="."><plain>This article presents a nursing standard designed to support Canadian <z:hpo ids='HP_0002664'>oncology</z:hpo> nurses in the key areas of counselling for patients initiating and continuing <z:chebi fb="0" ids="2038">azacitidine</z:chebi>, as well as nursing strategies for prevention and management of <z:chebi fb="0" ids="2038">azacitidine</z:chebi>-associated AEs </plain></SENT>
<SENT sid="5" pm="."><plain>Many of the general principles discussed in this nursing standard can be applied broadly to many diseases and treatments </plain></SENT>
</text></document>